🔗 Share this article

Given that the United States undertakes sweeping revisions to its immunization guidelines, an unexpected name has emerged unexpectedly: Høeg, an American of Danish descent sports medicine doctor and epidemiologist who initially gained attention by casting doubt on COVID-19 shots in the pandemic and has focused upon alleged deaths following COVID-19 vaccination in her brief time at the FDA.

Scheduled Shifts to Childhood Vaccine Program

Health officials had intended to unveil radical changes to the pediatric immunization program in December, bringing the US with Denmark’s vaccine program, it is understood – a major change that would put the US at odds with much of the global community with little proof for benefit. This reveal has been pushed back until the coming year.

Instead of the director of the vaccine center, Dr. Høeg is listed to speak at the gathering. She was just designated interim head of the FDA’s drug evaluation center, the fifth appointee to lead the office this year.

Consolidating Power at the Agency

Høeg's temporary position might represent a strengthened alliance between the drug and vaccine divisions as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it suggests a increased emphasis upon dismantling previously authorized vaccines at the FDA.

The new acting director has repeatedly called for ending specific childhood vaccine recommendations in the US in order to be more similar to Denmark, a country with comprehensive healthcare and a population about the size of the state of Wisconsin.

In her initial public appearances, she has continued to focus on immunizations – typically the purview of Prasad, director of the FDA’s CBER – as opposed to medication approval.

Doubts Over Expertise

Høeg has little discernible track record in pharmaceutical research, oversight or leadership, which has been customary for past directors of the CBER. She has worked at the FDA as a senior adviser to the agency head and the vaccine center since earlier this year.

“It seems she lacks to have any of the qualifications” for running the drug-regulation department, remarked a neurologist and psychiatrist. “She has not conducted a scientific study. She lacks experience in running a large organization. She is not an expert in pharmaceutical oversight.”

Former heads of CBER would “grasp laws and regulations and the science of pharmaceutical innovation”, commented Janet Woodcock. “Objectively, she lacks the type of experience that previous people who headed CBER have had.”

The drug center has an immense workload at the agency, the former commissioner emphasized.

“Many people just zeroes in on the novel medication approvals, but the off-patent medication office approves numerous generic medications. There’s a biosimilars program, over-the-counter program and more, and all of those have to be managed,” Woodcock explained. “The thing you neglect, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a substantial leadership component to the job, which oversees in excess of 5,000 staff members. “It is a huge administrative position, if you do it right,” the former official concluded.

Official Statement and Disputed Policies

In response to questions about Høeg’s fitness for the role and whether this selection indicates greater collaboration among agency officials on immunizations, a representative said that the “concerns rely on incorrect presumptions”.

“Her experience matches the responsibilities of her position,” the representative explained, noting the period Dr. Høeg spent counseling the FDA commissioner on “drug safety and approval science, including predictive safety algorithms and immunization monitoring”.

As acting director, Høeg assumes responsibility for the commissioner’s new fast-track approval initiative, a contentious one-day therapy clearance system that apparently concerned her preceding directors. “How are these therapies being picked for this fast-track system? Who takes the decisions?” Howard asked. “There is a lot of lack of transparency happening at the FDA right now.”

In general, he stated, “the agency appears to be shifting towards laxer regulations of most medications, aside from immunizations.”

Public History on Vaccines

Regarding vaccines, Dr. Høeg has a more documented, if troubling, past, Howard said. She released a study using unverified public submissions to estimate the incidence of myocarditis after COVID-19 immunization. She consulted for the Florida surgeon general Joseph Ladapo, who was said to have altered data to suggest Covid vaccinations are riskier than they are.

Included in her “policy goals” for the incoming government featured altering regulations for recently developed shots and ending “unnecessary” vaccines, she remarked post-election on a podcast. At the agency, Høeg has according to sources suggested barring young men from receiving Covid vaccines.

“She is an complete true believer who starts off with her beliefs and works backwards to fit the evidence in a very misleading, fraudulent manner,” Dr. Howard said.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg aligned with fellow contrarians, {like|